Recently we’ve started sharing personal testimonials from individuals who have used CBD infused products. Our goal with these stories is to help people who are going through similar tragedies and experiences learn about the benefits of cannabidiol. Most importantly, we want them to see how CBD may be helpful with relieving their symptoms and conditions.
One story we shared was from breast cancer survivor Meghan Kozeil who has used both CBD tinctures and creams during chemotherapy, radiation, and the healing process that comes after. She attributes her CBD treatment to helping tremendously with her nausea, never throwing up, increasing appetite, scar reductions from her mastectomy, burn relief during radiation and immune stability, as she never had a drop in blood cell counts.
Another story was about oral cancer survivor, Devin Koslap, who relied heavily on CBD creams for her scars and skin grafts. She shared that she had learned about CBD from Meghan who was having a lot of success with CBD-infused products, and thus the hope was contagious and well-received.
Now, the Food and Drug Administration (FDA) has also jumped on board and is asking the public for help as well. This was after the FDA declared that ‘CBD has been shown to be beneficial.’
CBD is one of more than 80 active cannabinoid chemicals in the Cannabis plant. CBD, unlike THC, does not produce euphoria or intoxication. CBDs have their effect mainly by interacting with specific receptors on cells in the brain and body that regulate many other processes within our central and peripheral nervous systems.
Earlier this week, the FDA officials put out the call for comments in the Federal Register. They are seeking information about CBD and how the UN’s World Health Organization (WHO) should designate it under the 1971 Convention on Psychotropic Substances.
FDA Deputy Commissioner Anna K. Abram sent out the notice acknowledging the following: “CBD has been shown to be beneficial in experimental models of several neurological disorders, including those of seizure and epilepsy.”
In addition, The United Nations is trying to figure out how to categorize cannabidiol (CBD), a non-psychoactive and medically beneficial cannabinoid contained in cannabis. It was UN officials, through the US Food and Drug Administration (FDA), that initiated the request for public involvement.
If you have information on or experience with, the use of CBD as a beneficial substance, the FDA encourages you to comment on the federal website. The public has until September 13th to do so.
As shared on a recent Leafly article, “CBD is one of 17 substances currently under scheduling review by the WHO. This process affects only the WHO and the United Nations. It does not directly deal with the status of CBD under the federal Controlled Substances Act—but it could have an indirect effect by influencing the outcome of the conflict over the federal categorization of cannabidiol.”
We are advocates for the truth and do our best to operate with as much integrity as possible within this industry. We will continue to share our views and welcome testimonials and stories from anyone who wants to be shared on our blog. If you are interested in sharing your story or experience with CBD, please email us at firstname.lastname@example.org